Recombinant Human IFN-epsilon Protein, CF

Recombinant Human IFN-epsilon (Catalog # 9667-ME/CF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 100‑500 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IFN-epsilon Protein, CF Summary

• Details of Functionality: Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED₅₀ for this effect is 100-500 ng/mL.
• Source: E. coli-derived human IFN-epsilon protein
  Leu22-Arg208 (Cys175Ser), with an N-terminal Met and a C-terminal 6-His tag
• Accession #: Q86WN2
• N-terminal Sequence: Met
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 23 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 23 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Citric Acid and CHAPS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IFN-epsilon Protein, CF

• IFNE
• IFN-E
• IFNE1PRO655
• IFNepsilon
• IFN-epsilon
• IFNT1
• Ifn-tau-11
• INFE1
• interferon epsilon 1
• interferon epsilon
• Interferon epsilon-1
• interferon tau-1
• interferon, epsilon
• interferon-epsilon
• MGC119018
• MGC119020

Background

Interferon-epsilon (IFN-epsilon) is a secreted, approximately 23 kDa member of the type I interferon family of molecules (1). Mature human IFN-epsilon shares 62% and 60% amino acid sequence identity with  rat and mouse IFN-epsilon, respectively. IFN-epsilon signals through IFN‑alpha / beta R1 and IFN‑alpha / beta R2 and contributes to TNF-alpha induced signaling (2, 3). It is constitutively expressed in epithelial cells lining the lung, intestines, testes, and female reproductive tract, and it is further up-regulated in the uterus by estrogen (2-6). IFN-epsilon provides mucosal barrier protection against the pathogens Chlamidia and Herpes simplex virus 2 (2). It induces B cell activation, attraction of CD8⁺ T cells to sites of virus infection and directly mediates protection against viral and bacterial genital infections (5, 7). Differential regulation of genes related to central nervous system by recombinant human IFN-epsilon suggests its role in maintenance of the structure and function of brain (8).

1. Wijesundara, D.K. et al. (2014) Front. Immunol. 5:412.
2. Fung, K.Y. et al. (2013) Science 339:1088.
3. Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
4. Demers, A. et al. (2014) J. Leukoc. Biol. 96:1101.
5. Xi, Y. et al. (2012) Mucosal Immunol. 5:610.
6. Hermant, P. et al. (2013) PLoS One 8:e71320.
7. Day, S.L. et al. (2008) J. Immunol. 180:7158.
8. Peng, Fu-Wang et.al. (2007) Protein Expression and Purification 53:356.

Bioinformatics

• Uniprot:
  • Q86WN2()